Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Mayo Clinic
Mayo Clinic
University of California, San Francisco
QuantumLeap Healthcare Collaborative
Mayo Clinic
Essen Biotech
Royal Marsden NHS Foundation Trust
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
University of Alabama at Birmingham
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Mayo Clinic
University of Southern California
Memorial Sloan Kettering Cancer Center
Institut Bergonié
Maria Sklodowska-Curie National Research Institute of Oncology
Memorial Sloan Kettering Cancer Center
Gustave Roussy, Cancer Campus, Grand Paris
Seattle Children's Hospital
Memorial Sloan Kettering Cancer Center
University of California, Irvine
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Yonsei University
University of Iowa
Memorial Sloan Kettering Cancer Center
Sarcoma Oncology Research Center, LLC
Saint John's Cancer Institute
Fred Hutchinson Cancer Center
University of Miami
Columbia University
UNICANCER
Wake Forest University Health Sciences
Sunnybrook Health Sciences Centre
Herlev and Gentofte Hospital
Oslo University Hospital
Fred Hutchinson Cancer Center
Oslo University Hospital
Sarcoma Alliance for Research through Collaboration
Assistance Publique - Hôpitaux de Paris
Western Regional Medical Center
Peter MacCallum Cancer Centre, Australia